Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BioMark Diagnostics Inc. (BUX) has provided updates regarding the ongoing clinical trials using its liquid biopsy test for early cancer detection
  • Enrollment for its lung cancer screening study has exceeded 1000 participants in less than one year
  • It also recruited its first international patient recruited as part of a European prospective lung cancer screening trial in France called the ILYAD study
  • The company signed a collaborative research agreement with an Indian university
  • Lastly, the company intends to validate the test as a laboratory-developed test within the next year
  • BioMark Diagnostics Inc. (BUX) is unchanged, trading at $0.23 per share as of 10:59 a.m. EST

BioMark Diagnostics Inc. (BUX) has provided updates regarding the ongoing clinical trials using its liquid biopsy test for early cancer detection.

BioMark is a liquid biopsy company developing a molecular diagnostics technology platform that uses large-scale cell studies (metabolomics) and machine learning algorithms for new cancer diagnostics and to improve cancer prognosis. Its technology can also be used for measuring response to treatment.

The company stated that enrollment for its lung cancer screening study has exceeded 1000 participants in less than one year. The screening will combine BioMark’s metabolomics liquid biopsy test with traditional screening methods to help at-risk patients get access to an accurate and accessible lung cancer screening program.

BioMark also announced it has recruited its first international patient recruited as part of a European prospective lung cancer screening trial in France called the ILYAD study. The test being developed from this study would screen nearly four million eligible individuals aged between 50 to 75 and have a history of heavy smoking.

Additionally, BioMark recently signed a collaborative research agreement with the Delhi Pharmaceutical Sciences and Research University in India and is currently designing a clinical protocol to evaluate a cost-effective, highly sensitive and easy-to-deploy lung cancer screening platform.  

Lastly, the company intends to validate the test as a laboratory-developed test. The test will be available through its Quebec-based laboratory within nine to 12 months.

BioMark Diagnostics Inc. (BUX) is unchanged, trading at $0.23 per share as of 10:59 a.m. EST.


More From The Market Herald

" @ the Bell: Markets tumble amid rate worries

Canada’s main stock index was weighed down on Monday by commodity-linked and financial stocks. The telecom and utilities sectors posted some gains.
Dolly Varden Silver Corporation - President & CEO, Shawn Khunkhun.

" Dolly Varden Silver (TSXV:DV) reports highest-grade silver assay found so far on the Kitsault Valley Property

Dolly Varden Silver Corporation (DV) discovered the highest-grade silver assay found so far on the Kitsault Valley Property.

" Black Tusk Resources (CSE:TUSK) acquiring PegaLith Project

Black Tusk Resources (TUSK) has signed a $361,000 share purchase agreement to acquire 1396427 BC Ltd.

" Deep South Resources (TSXV:DSM) closes oversubscribed non-brokered private placement

Deep-South Resources (DSM) has closed the final tranche of an oversubscribed, non-brokered private placement for gross proceeds of $490,000.